-
1
المؤلفون: Olivier J. van Not, Melissa M. de Meza, Alfons J.M. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel, Jesper van Breeschoten, Jan-Willem B. de Groot, Geke A.P. Hospers, Rawa K. Ismail, Ellen Kapiteijn, Djura Piersma, Roos S. van Rijn, Marion A.M. Stevense-den Boer, Astrid A.M. van der Veldt, Gerard Vreugdenhil, Han J. Bonenkamp, Marye J. Boers-Sonderen, Willeke A.M. Blokx, Michel W.J.M. Wouters, Karijn P.M. Suijkerbuijk
المساهمون: Medical Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, Obstetrics and gynaecology, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
المصدر: European journal of cancer (Oxford, England : 1990), 167, 70-80. Elsevier Ltd.
van Not, O J, de Meza, M M, van den Eertwegh, A J M, Haanen, J B, Blank, C U, Aarts, M J B, van den Berkmortel, F W P J, van Breeschoten, J, de Groot, J-W B, Hospers, G A P, Ismail, R K, Kapiteijn, E, Piersma, D, van Rijn, R S, Stevense-den Boer, M A M, van der Veldt, A A M, Vreugdenhil, G, Bonenkamp, H J, Boers-Sonderen, M J, Blokx, W A M, Wouters, M W J M & Suijkerbuijk, K P M 2022, ' Response to immune checkpoint inhibitors in acral melanoma : A nationwide cohort study ', European Journal of Cancer, vol. 167, pp. 70-80 . https://doi.org/10.1016/j.ejca.2022.02.026
European Journal of Cancer, 167, 70-80. ELSEVIER SCI LTD
European Journal of Cancer, 167, pp. 70-80
European Journal of Cancer, 167, 70-80
European Journal of Cancer, 167, 70-80. Pergamonمصطلحات موضوعية: Cancer Research, Skin Neoplasms, Survival, Melanoma/mortality, THERAPY, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], SUBTYPES, Cohort Studies, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], Immune checkpoint inhibitors, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Skin Neoplasms/drug therapy, Humans, Prospective Studies, Melanoma, OUTCOMES, Response, KIT, EFFICACY, Nivolumab/adverse effects, Ipilimumab, Immune Checkpoint Inhibitors/therapeutic use, MUCOSAL, Nivolumab, Oncology, ARM, Immunotherapy, Ipilimumab/therapeutic use
وصف الملف: application/pdf
-
2
المؤلفون: Sylvain Raoul Simeni Njonnou, Sandrine Aspeslagh, Marie-Josiane Ntsama Essomba, Marie-Lucie Racu, Fernando Kemta Lekpa, Frédéric Vandergheynst
المساهمون: Brussels Heritage Lab, Laboratory of Molecular and Medical Oncology, Clinical sciences, Medical Oncology
مصطلحات موضوعية: immune checkpoint inhibitors, Sjogren's Syndrome, Adrenocorticotropic Hormone, oncology, Humans, Melanoma/drug therapy, General Medicine, Neoplasm Recurrence, Local, Nivolumab/adverse effects, Tomography, X-Ray Computed, Aged
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fc3c99386df1959c242a9a6cd2f3279
https://doi.org/10.1186/s13256-022-03663-6 -
3
المؤلفون: Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross-Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwenaëlle Gravis, Nadine Houede, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, Nicolas Doumerc, Philippe Paparel, Jean-Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, Géraldine Pignot, Elena Braychenko, Stefano Caruso, Cheng-Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougouïn, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman-Rossi, Wolf Herman Fridman, Catherine Sautès-Fridman, Stéphane Oudard
المساهمون: Cancer Research and Personalized Medicine - CARPEM [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie [Paris] (ARTIC), Institut Mutualiste de Montsouris (IMM), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Hôpital Saint-André, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Centre Eugène Marquis (CRLCC), Institut de Cancérologie de Strasbourg Europe (ICANS), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie du GARD ICG - CHU Nîmes (Instit Cancéro - GARD), Clinique d'Oncologie et de Radiothérapie [Tours] (CORAD), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Hôpital Foch [Suresnes], Service des Explorations Fonctionnelles Physiologiques [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hospices Civils de Lyon (HCL), Nouvel Hôpital Civil de Strasbourg, Service de Néphrologie-Dialyse-Transplantation rénale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)
المصدر: Lancet Oncology
Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩مصطلحات موضوعية: MESH: Humans, MESH: Carcinoma, Renal Cell / drug therapy, MESH: Angiogenesis Inhibitors / adverse effects, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Neoplasm Staging, MESH: Male, MESH: Prospective Studies, MESH: Ipilimumab, MESH: Lipase, Oncology, MESH: Tumor Microenvironment, MESH: Sunitinib, MESH: Biomarkers, MESH: Antineoplastic Combined Chemotherapy Protocols / adverse effects, MESH: Female, MESH: Nivolumab / adverse effects, MESH: Protein Kinase Inhibitors / adverse effects
-
4
المؤلفون: Andre M. Murad, Jean-Christophe Pignon, Alain Ravaud, Abdallah Flaifel, Judit Kocsis, Scott S. Tykodi, Yuko Ishii, Shruti Shally Saggi, Sabina Signoretti, Sumanta K. Pal, Thomas Powles, Miriam Ficial, Brian I. Rini, Philippe Barthélémy, Saby George, Osvaldo Arén Frontera, David F. McDermott, Robert J. Motzer, M. Brent McHenry, Michael R. Harrison, Frede Donskov, Toni K. Choueiri, Nizar M. Tannir, Jeronimo R. Rodriguez-Cid
المصدر: Ann Transl Med
Tannir, N M, Signoretti, S, Choueiri, T K, McDermott, D F, Motzer, R J, Flaifel, A, Pignon, J C, Ficial, M, Frontera, O A, George, S, Powles, T, Donskov, F, Harrison, M R, Emy, P B, Tykodi, S S, Kocsis, J, Ravaud, A, Rodriguez-Cid, J R, Pal, S K, Murad, A M, Ishii, Y, Saggi, S S, Brent McHenry, M & Rini, B I 2021, ' Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma ', Clinical Cancer Research, vol. 27, no. 1, pp. 78-86 . https://doi.org/10.1158/1078-0432.CCR-20-2063مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, DOXORUBICIN, Population, Ipilimumab, Protein Serine-Threonine Kinases, Sunitinib/therapeutic use, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Renal cell carcinoma, Internal medicine, PD-1, Antineoplastic Combined Chemotherapy Protocols, Post-hoc analysis, Sunitinib, Carcinoma, medicine, Humans, Hippo Signaling Pathway, education, Carcinoma, Renal Cell, education.field_of_study, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Nivolumab/adverse effects, medicine.disease, SYSTEMIC THERAPY, Kidney Neoplasms, Confidence interval, Kidney Neoplasms/drug therapy, Editorial Commentary, Nivolumab, 030104 developmental biology, ANTIBODY, GEMCITABINE, Oncology, 030220 oncology & carcinogenesis, Carcinoma, Renal Cell/drug therapy, SURVIVAL, Ipilimumab/adverse effects, Immunotherapy, business, medicine.drug
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ef4fae16505a538074156c51ab25a
https://doi.org/10.1158/1078-0432.ccr-20-2063 -
5
المؤلفون: Marco Zezza, Nelly Pitteloud, Haithem Chtioui, Laura Marino, Faiza Lamine, Carine Mekoguem, Christophe Kosinski
المصدر: BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Endocrine Disorders
BMC endocrine disorders, vol. 19, no. 1, pp. 144مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, Skin Neoplasms, Combination therapy, Diabetic ketoacidosis, endocrine system diseases, Endocrinology, Diabetes and Metabolism, Case Report, Ipilimumab, Type 2 diabetes, Immune checkpoint inhibitor, lcsh:Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Antineoplastic Agents, Immunological, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, 030212 general & internal medicine, Endocrinopathies, Melanoma, Autoimmune adverse events, Aged, 80 and over, Type 1 diabetes, lcsh:RC648-665, business.industry, Type 2 Diabetes Mellitus, General Medicine, Middle Aged, medicine.disease, Acute Disease, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Diabetes Mellitus, Type 1/chemically induced, Diabetes Mellitus, Type 1/diagnosis, Diabetes Mellitus, Type 1/pathology, Female, Ipilimumab/administration & dosage, Ipilimumab/adverse effects, Melanoma/drug therapy, Melanoma/pathology, Nivolumab/administration & dosage, Nivolumab/adverse effects, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Diabetes Mellitus, Type 1, Nivolumab, 030220 oncology & carcinogenesis, business, medicine.drug
وصف الملف: application/pdf
-
6
المؤلفون: Monique C. Minnema, Margaret A. Shipp, Stephen M. Ansell, Nishitha Reddy, Scott J. Rodig, Jonathon B. Cohen, Selda Samakoglu, Kazunobu Kato, Margaretha G.M. Roemer, Sarit Assouline, Philippe Armand, Anne Sumbul, Michelle Poon, Peter Johnson, Azra H. Ligon, Manish Sharma, John M. Timmerman, Andrew Grigg
المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(6), 481. American Society of Clinical Oncology
مصطلحات موضوعية: Male, Oncology, Diffuse/drug therapy, Cancer Research, Time Factors, Lymphoma, Programmed Cell Death 1 Receptor, Phases of clinical research, Transplantation, Autologous/adverse effects, Clinical Trial, Phase II, Antineoplastic Agents, Immunological, immune system diseases, hemic and lymphatic diseases, Immunological/adverse effects, 80 and over, Treatment Failure, Non-U.S. Gov't, Aged, 80 and over, Research Support, Non-U.S. Gov't, Programmed Cell Death 1 Receptor/antagonists & inhibitors, Remission Induction, Hematopoietic Stem Cell Transplantation, ORIGINAL REPORTS, Middle Aged, Clinical Trial, Progression-Free Survival, Phase II, Multicenter Study, Nivolumab, Lymphoma, Large B-Cell, Diffuse/drug therapy, Disease Progression, Female, Lymphoma, Large B-Cell, Diffuse, Chromosomes, Human, Pair 9, Human, Pair 9, Antineoplastic Agents, Immunological/adverse effects, Adult, medicine.medical_specialty, Autologous/adverse effects, Antineoplastic Agents, Research Support, Transplantation, Autologous, Chromosomes, N.I.H, Young Adult, Research Support, N.I.H., Extramural, Refractory, Internal medicine, Large B-Cell, Journal Article, medicine, Humans, Autologous transplantation, Progression-free survival, Hematopoietic Stem Cell Transplantation/adverse effects, Aged, Transplantation, business.industry, Extramural, Nivolumab/adverse effects, medicine.disease, business, Diffuse large B-cell lymphoma
وصف الملف: text; image/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bd249e2e8165cc0d45938a170ea405
https://doi.org/10.1200/jco.18.00766 -
7
المؤلفون: Marija Gamulin, Eric Nham, Deni Rkman, Zrna Antunac, null Golubić, Robert Likić
المصدر: Croatian Medical Journal
Volume 61
Issue 4مصطلحات موضوعية: Carcinoma, Renal Cell / pathology, Adult, Male, medicine.medical_specialty, Nivolumab / therapeutic use, Anemia, Gastroenterology, Resaerch Article, Antineoplastic Agents, Immunological, Renal cell carcinoma, Internal medicine, Antineoplastic Agents, Immunological / therapeutic use, medicine, renal cell cancer, nivolumab, Humans, Nivolumab / adverse effects, Antineoplastic Agents, Immunological / adverse effects, Adverse effect, Carcinoma, Renal Cell, Pneumonitis, Aged, Retrospective Studies, Aged, 80 and over, Carcinoma, Renal Cell / drug therapy, business.industry, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Rash, Kidney Neoplasms, Nivolumab, Treatment Outcome, Tolerability, Female, Kidney Neoplasms / pathology, medicine.symptom, Kidney Neoplasms / drug therapy, business
وصف الملف: application/pdf
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d807a701ee3b39fe7fd1be726737505
https://www.bib.irb.hr/1263395 -
8
المؤلفون: C. de Lorenzi, Marem Abosaleh, A. Vuilleumier, Guerkan Kaya, Raphaël André
المصدر: Annales de dermatologie et de vénéréologie, Vol. 147, No 3 (2020) pp. 221-227
مصطلحات موضوعية: Male, medicine.medical_specialty, Renal Cell/drug therapy, medicine.medical_treatment, Bullous lichen planus, Vesiculobullous/chemically induced, Context (language use), Antineoplastic Agents, Dermatology, Pembrolizumab, Skin Diseases, Lichen Planus/chemically induced, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Agents, Immunological, stomatognathic system, Immunological/adverse effects, Medicine, Humans, Adverse effect, skin and connective tissue diseases, Carcinoma, Renal Cell, Aged, ddc:616, Skin Diseases, Vesiculobullous, integumentary system, business.industry, Carcinoma, Lichen Planus, Immunotherapy, Nivolumab/adverse effects, Kidney Neoplasms, Discontinuation, stomatognathic diseases, Kidney Neoplasms/drug therapy, Nivolumab, business, Medical literature
-
9
المؤلفون: Annabel Meireson, Piet Ost, Teofila Seremet, Jo Van Dorpe, Liesbeth Ferdinande, Nora Sundahl, Bart Neyns, Lieve Brochez, Vibeke Kruse
المساهمون: Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Laboratory of Molecullar and Cellular Therapy
مصطلحات موضوعية: Oncology, Male, Cancer Research, Radiosurgery/adverse effects, Skin Neoplasms, Melanoma/blood, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Programmed Cell Death 1 Receptor/blood, Pembrolizumab, Kaplan-Meier Estimate, Chemoradiotherapy/adverse effects, 030218 nuclear medicine & medical imaging, GTP Phosphohydrolases, 0302 clinical medicine, Antineoplastic Agents, Immunological, Clinical endpoint, Melanoma, Skin Neoplasms/blood, Medicine(all), Radiation, GTP Phosphohydrolases/blood, Chemoradiotherapy, DNA, Neoplasm, Middle Aged, Progression-Free Survival, Nivolumab, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Female, medicine.drug, Proto-Oncogene Proteins B-raf, Adult, Antineoplastic Agents, Immunological/adverse effects, medicine.medical_specialty, DNA, Neoplasm/blood, Ipilimumab, Radiosurgery, Drug Administration Schedule, 03 medical and health sciences, Internal medicine, medicine, Biomarkers, Tumor, Humans, Radiology, Nuclear Medicine and imaging, Progression-free survival, Aged, Proto-Oncogene Proteins B-raf/blood, business.industry, Membrane Proteins/blood, Membrane Proteins, medicine.disease, Nivolumab/adverse effects, Radiation therapy, Biomarkers, Tumor/blood, business, Progressive disease
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1f6019cfc276207deb92a753bddb0b2
https://biblio.vub.ac.be/vubir/phase-2-trial-of-nivolumab -combined-with-stereotactic-body-radiation-therapy-in-patients-with-metastatic-or-locally-advanced-inoperable-melanoma(707a28c4-923a-46bd-96f3-69c0fb0f2a41).html -
10
المؤلفون: Vincent Pillonel, Olivier Michielin, Andreas F. Hottinger, Luis Schiappacasse, Veronica Aedo-Lopez, Gregoire Berthod, Vincent Dunet, Solange Peters
المصدر: Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol. 7, no. 1, pp. 336
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)مصطلحات موضوعية: 0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, CNS demyelination, Immunology, Remission, Spontaneous, Spontaneous remission, Case Report, Metastatic melanoma, lcsh:RC254-282, Asymptomatic, 03 medical and health sciences, Immune checkpoint inhibitors, 0302 clinical medicine, Antineoplastic Agents, Immunological, Immune related adverse events, Internal medicine, medicine, Image Processing, Computer-Assisted, Immunology and Allergy, Humans, Antineoplastic Agents, Immunological/administration & dosage, Antineoplastic Agents, Immunological/adverse effects, Asymptomatic Diseases, Demyelinating Diseases/diagnosis, Demyelinating Diseases/etiology, Magnetic Resonance Imaging, Melanoma/complications, Melanoma/diagnosis, Melanoma/drug therapy, Nivolumab/administration & dosage, Nivolumab/adverse effects, Neurological toxicities, Nivolumab, Melanoma, Pharmacology, business.industry, Immunotherapy, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, medicine.disease, Hyperintensity, 030104 developmental biology, 030220 oncology & carcinogenesis, Molecular Medicine, medicine.symptom, business, Demyelinating Diseases
وصف الملف: application/pdf
Full Text via ClinicalKey 
Find this article in full text from Springer Verlag.